LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

89.66 -0.94

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

87.87

Максимум

91.98

Ключови измерители
By Trading Economics
Приходи	-8.1M -56M
Продажби	2.9M 60M
EPS	-0.83
Марж на печалбата	-92.559
Служители	414
EBITDA	-9.7M -52M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+50.89% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	151M 6B
Предишно отваряне	90.6
Предишно затваряне	89.66

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.05.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21.05.2026 г., 16:49 ч. UTC

Печалби

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21.05.2026 г., 16:26 ч. UTC

Значими двигатели на пазара

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

21.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21.05.2026 г., 22:33 ч. UTC

Придобивния, сливания и поглъщания

Conduent to Sell Public Transit Business to Modaxo for $164M

21.05.2026 г., 21:53 ч. UTC

Печалби

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21.05.2026 г., 21:02 ч. UTC

Печалби

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21.05.2026 г., 20:55 ч. UTC

Печалби

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21.05.2026 г., 20:30 ч. UTC

Горещи акции

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21.05.2026 г., 20:20 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.05.2026 г., 20:20 ч. UTC

Пазарно говорене

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21.05.2026 г., 20:20 ч. UTC

Печалби

Webull 1Q Adj EPS 3c >BULL

21.05.2026 г., 20:20 ч. UTC

Печалби

Webull 1Q Rev $159.9M >BULL

21.05.2026 г., 20:18 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Easing in Early May -- Market Talk

21.05.2026 г., 20:18 ч. UTC

Печалби

Webull 1Q Loss/Shr 4c

21.05.2026 г., 19:43 ч. UTC

Пазарно говорене

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21.05.2026 г., 18:58 ч. UTC

Печалби

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21.05.2026 г., 18:15 ч. UTC

Пазарно говорене

Gold Higher For Second Consecutive Day -- Market Talk

21.05.2026 г., 17:40 ч. UTC

Пазарно говорене

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21.05.2026 г., 17:04 ч. UTC

Пазарно говорене

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21.05.2026 г., 17:01 ч. UTC

Печалби

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Stellantis Targets Distant but Constructive -- Market Talk

21.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

50.89% нагоре

12-месечна прогноза

Среден 136.77 USD 50.89%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.